Strand Therapeutics is a biopharmaceutical company applying synthetic biology to RNA therapeutics to develop single dose mRNA treatments.
Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 28, 2022 | Series A | $45M | 4 |
FPV Ventures
|
— | Detail |
| Nov 9, 2021 | Grant | $400K | 1 |
National Cancer Institute
|
— | Detail |
| Aug 4, 2021 | Grant | $800K | 1 |
National Cancer Institute
|
— | Detail |
| Jun 23, 2021 | Series A | $52M | 5 | — | — | Detail |
| Jun 4, 2019 | Seed | $6M | 4 |
Playground Global
|
— | Detail |
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Aug 10, 2021
WorkMotion
|
Series A | €20.48M | Compliance | — |
|
Mar 9, 2021
WorkMotion
|
Angel | €2.20M | Compliance | — |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
FPV Ventures
|
Yes | Series A |
National Cancer Institute
|
Yes | Grant |
Eli Lilly & Company Foundation
|
— | Series A |
Playground Global
|
— | Series A |
Potentum partners
|
— | Series A |
ANRI
|
— | Series A |
BeiGene
|
— | Series A |
Camford Capital
|
— | Series A |
|
|
— | Series A |
Creative Destruction Lab (CDL)
|
— | Seed |